Ranibizumab Biosimilar from IIT Delhi

Technology Offering

  • Upstream and downstream process development complete
  • Titer of 50 mg purified protein/ L reactor
  • Purification yield of 23 ± 2 % (refolding to formulation)
  • Purification yield of 70% (capto L chromatography to formulation)
  • Novel refolding process with a refolding yield of 30-35% vs the industry standard of 15%.
  • Analytical and functional similarity to innovator molecule has been established
  • Novel continuous processing platform reduces the cost of manufacturing by 80% for clinical and 75% for commercial production.

Current Technology Status

  • Development of Hypotheses and Experimental Designs Done
  • Non-clinical in-vitro studies: Physicochemical characterization for Biosimilarity Done
  • Non-clinical in-vitro studies: Functional characterization for Biosimilarity Done

Market Potential

The global age-related macular degeneration (AMD) market stood at $ 1.58 billion in 2020 and is projected to reach $ 2.64 billion by 2026, growing at CAGR of 8.93% between 2021 and 2026. There are 2 global players and 1 Indian company working on Ranibizumab biosimilar.

About Trastuzumab

Ranibizumab, sold by Genentech (Roche)/Novartis under the brand name Lucentis is a recombinant humanized monoclonal antibody and VEGF-A antagonist. It is used in the treatment of eye disorders such as neovascular (wet) age-related macular degeneration (wAMD), Macular edema following retinal vein occlusion (RVO), Diabetic macular edema (DME), and others. However, treatment costs are prohibitively high, costing upwards of 150 dollars per injection. Thus, there is an urgent need for process innovation to reduce costs.

Contact Information

TTO Home Page: www.techex.in

Address: TechEx.in, Venture Center, 100, NCL Innovation Park, Dr Homi Bhabha Rd, Pune-411008 India

Phone: +91-9156465146 

Email: tto@venturecenter.co.in